{4-amino-2-[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)-phenylamino]-thiazol-5-yl}-(3,5-difluoro-phenyl)-methanone | 867292-01-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: {4-amino-2-[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)-phenylamino]-thiazol-5-yl}-(3,5-difluoro-phenyl)-methanone
• 英文别名: [4-Amino-2-[4-[4-(3-hydroxypiperidin-1-yl)piperidin-1-yl]anilino]-1,3-thiazol-5-yl]-(3,5-difluorophenyl)methanone
• CAS: 867292-01-1
• 化学式: C₂₆H₂₉F₂N₅O₂S
• 分子量: 513.611
• InChiKey: PLBSHXQKJBATNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  123
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• Diaminothiazoles
  申请人：Ding Qingjie

  公开号：US20050239843A1

  公开（公告）日：2005-10-27

  Novel diaminothiazoles of formula (I): are discussed. These compounds selectively inhibit the activity of Cdk4 and are thus useful in the treatment or control of cancer, in particular, the treatment or control of solid tumors. This invention also provides pharmaceutical compositions containing such compounds and methods of treating or controlling cancer, most particularly, the treatment or control of breast, lung, colon, and prostate tumors.

  讨论了公式（I）的新型二氨基噻唑化合物。这些化合物选择性地抑制Cdk4的活性，因此在癌症的治疗或控制中很有用，特别是在实体肿瘤的治疗或控制方面。该发明还提供了含有这类化合物的药物组合物以及治疗或控制癌症的方法，尤其是治疗或控制乳腺、肺、结肠和前列腺肿瘤的方法。
• NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1740576B1

  公开（公告）日：2009-07-01
• CRYTALLINE FORMS OF A PYRAZOLO `3, 4-C Ü PYRIDINE FACTOR XA INHIBITOR
  申请人：Bristol-Myers Squibb Company

  公开号：EP1819703A1

  公开（公告）日：2007-08-22
• US7211576B2
  申请人：——

  公开号：US7211576B2

  公开（公告）日：2007-05-01
• [EN] CRYTALLINE FORMS OF A PYRAZOLO `3, 4-C ! PYRIDINE FACTOR XA INHIBITOR<br/>[FR] FORMES CRISTALLINES D'INHIBITEUR DE FACTEUR XA PYRAZOLO `3, 4-C ! PYRIDINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2006036927A1

  公开（公告）日：2006-04-06

  The instant invention provides crystalline forms of 1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1(2H)pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions.